Inhibitor of aldo-keto reductase 1C1 (AKR1C1)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Product Categories

Research Area

5-bromo-3-phenyl Salicylic Acid

Item No. 13379

Technical Information
Formal Name
5-bromo-2-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
CAS Number
99514-99-5
Molecular Formula
C13H9BrO3
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 20 mg/mlDMF:PBS (pH 7.2) (1:9): 0.1 mg/mlDMSO: 20 mg/mlEthanol: 3 mg/ml
λmax
220, 301 nm
SMILES
BrC1=CC(C2=CC=CC=C2)=C(O)C(C(O)=O)=C1
InChi Code
InChI=1S/C13H9BrO3/c14-9-6-10(8-4-2-1-3-5-8)12(15)11(7-9)13(16)17/h1-7,15H,(H,16,17)
InChi Key
HUQWWRUNBHYQLK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    The aldo-keto reductase (AKR) enzymes constitute a family of related NADPH-dependent oxidoreductases. The 1C subfamily (AKR1C) includes four human hydroxysteroid dehydrogenases (HSDs), with AKR1C1 being a 20α-HSD and the other three being 3α-HSDs. AKR1C1 metabolizes progesterone to an inactive progestin, 20α-hydroxy progesterone.1 In addition, AKR1C1 actions have been implicated in cancer and in the processing of neuroactive steroids involved in brain function.2,3,4,5 5-bromo-3-phenyl Salicyclic acid selectively inhibits AKR1C1 (Ki = 140 nM) over AKR1C2 (K1 = 1.97 µM) and AKR1C3 (Ki = 21 µM).6 It does not inhibit AKR1C4 at 100 µM.6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Zhang, Y., Dufort, I., Rheault, P., et alCharacterization of a human 20α-hydroxysteroid dehydrogenase. J. Mol. Endocrinol. 25(2), 221-228 (2000).

    2. Lewis, M.J., Wiebe, J.P., and Heathcote, J.G. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4, 27 (2004).

    3. Wang, H.W., Lin, C.P., Chiu, J.H., et alReversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int. J. Cancer 120(9), 2019-2027 (2007).

    4. Belelli, D., Herd, M.B., Mitchell, E.A., et alNeuroactive steroids and inhibitory neurotransmission: Mechanisms of action and physiological relevance. Neuroscience 138(3), 821-829 (2006).

    5. Usami, N., Yamamoto, T., Shintani, S., et alSubstrate specificity of human 3(20)α-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25(4), 441-445 (2002).

    6. El-Kabbani, O., Scammells, P.J., Gosling, J., et alStructure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20α-hydroxysteroid dehydrogenase (AKR1C1). J. Med. Chem. 52(10), 3259-3264 (2009).